Nishio Makoto

Research field (1)： Respiratory medicine

Research theme for competitive and other funds (10)：

2016 - 2019 Detection of ALK fusion genes in plasma exosomes
2016 - 2019 Drug resistance mechanisms and therapeutic strategies in rare driver oncogene positive cancers
2016 - 2019 Discovery of drug resistant mechnism by kinome analysis using patient derived cultured cells
2015 - 2018 Intratumoral heterogeneity of lung cancer and its influence on the companion diagnostics
2013 - 2017 Evaluation of patients' understanding regarding caner clinical trials

Show all

Papers (325)：

Hironori Ninomiya, Yukiko Sato, Kentaro Inamura, Akito Dobashi, Kengo Takeuchi, Hiroki Mitani, Mingyon Mun, Makoto Nishio, Yuichi Ishikawa. Neuroendocrine and squamous cell phenotypes of NUT carcinoma are potential diagnostic pitfalls that discriminating it from mimickers, such as small cell and squamous cell carcinoma. Diagnostic pathology. 2024. 19. 1. 27-27
Nobuyuki Kondo, Takahiro Utsumi, Yuki Shimizu, Ai Takemoto, Tomoko Oh-Hara, Ken Uchibori, Sophia Subat-Motoshi, Hironori Ninomiya, Kengo Takeuchi, Makoto Nishio, et al. MIG6 loss confers resistance to ALK/ROS1 inhibitors in NSCLC through EGFR activation by low-dose EGF. JCI insight. 2023
Makoto Nishio, Yuichiro Ohe, Satoshi Ikeda, Toshihide Yokoyama, Hidetoshi Hayashi, Tatsuro Fukuhara, Yuki Sato, Hiroshi Tanaka, Katsuyuki Hotta, Shunichi Sugawara, et al. First-line nivolumab plus ipilimumab in metastatic non-small cell lung cancer: 5-year outcomes in Japanese patients from CheckMate 227 Part 1. International journal of clinical oncology. 2023. 28. 10. 1354-1368
Makoto Nishio, Yuichiro Ohe, Satoshi Ikeda, Toshihide Yokoyama, Hidetoshi Hayashi, Tatsuro Fukuhara, Yuki Sato, Hiroshi Tanaka, Katsuyuki Hotta, Shunichi Sugawara, et al. Correction to: First-line nivolumab plus ipilimumab in metastatic non-small cell lung cancer: 5-year outcomes in Japanese patients from CheckMate 227 Part 1. International journal of clinical oncology. 2023. 28. 10. 1369-1370
Tatsuya Yoshida, Toru Kumagai, Ryo Toyozawa, Ryohei Katayama, Makoto Nishio, Takashi Seto, Koichi Goto, Nobuyuki Yamamoto, Yuichiro Ohe, Kentarou Kudou, et al. Brigatinib in Japanese patients with ALK-positive non-small-cell lung cancer: Final results of the phase 2 J-ALTA trial. Cancer science. 2023. 114. 9. 3698-3707

ｍore...

MISC (488)：

Yasushi Yatabe, Makoto Nishio, Toshiaki Takahashi, Kazumi Nishino, Yasumasa Yoshiki, Kanae Togo, Birol Emir, Laura Iadeluca, Kazuto Nishio. Real-world data of multiple diagnostic biomarker testing for lung cancer patients in Japan. ANNALS OF ONCOLOGY. 2021. 32. S300-S300
網野喜彬, 植松慎矢, 吉澤孝浩, 内堀健, 堀池篤, 西尾誠人. ニボルマブによる重症免疫関連有害事象治療中のサイトメガロウイルス感染に注意を要した1例. 日本呼吸器学会誌. 2021. 10. 1. 33-36
有安亮, 内堀健, 田中寿志, 宮内栄作, 川嶋庸介, 大柳文義, 堀池篤, 酒谷俊雄, 齊木雅史, 丹保裕一, et al. 化学放射線療法後デュルバルマブの投与回避要因(TOPGAN2020-01). 肺癌. 2020. 60. 7. 966-971
二宮浩範, 有安亮, 柳谷典子, 北園聡, 内堀健, 文敏景, 竹内賢吾, 西尾誠人. これからの病理診断成功するオンコマインの病理検体とは?. 肺癌. 2020. 60. 6. 467-467
吉田寛, 柳谷典子, 坂本博昭, 戸塚猛大, 網野喜彬, 植松慎矢, 長谷川司, 吉澤孝浩, 有安亮, 内堀健, et al. 気管支鏡検査で得た細胞診検体によるEGFR遺伝子検査の精度の検討. 肺癌. 2020. 60. 6. 539-539

ｍore...

※ Researcher’s information displayed in J-GLOBAL is based on the information registered in researchmap. For details, see here.

Return to Previous Page